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Summary
We have developed a mouse model for ovarian carcinoma by using an avian retroviral gene delivery technique for the
introduction of multiple genes into somatic ovarian cells of adult mice. Ovarian cells from transgenic mice engineered to
express the gene encoding the avian receptor TVA were efficiently infected in vitro with multiple vectors carrying coding
sequences for oncogenes and marker genes. When target cells were derived from TVA transgenic mice deficient for p53,
the addition of any two of the oncogenes c-myc, K-ras, and Akt were sufficient to induce ovarian tumor formation when
infected cells were injected at subcutaneous, intraperitoneal, or ovarian sites. We demonstrated that the ovarian surface
epithelium is the precursor tissue for these ovarian carcinomas, and that introduction of oncogenes causes phenotypic
changes in the ovarian surface epithelial cells. The induced ovarian tumors in mice resembled human ovarian carcinomas
in their rapid progression and intraperitoneal metastatic spread.
Introduction oncogenes such as c-myc, K-ras, and Akt, whose products are
involved in the control of growth stimulatory and cell death
pathways, are often amplified or mutated in ovarian cancer.Ovarian carcinoma is the fifth most common cause of cancer
among women in the United States, with more than 23,000 new Amplification of c-myc has been reported in approximately 30%
of ovarian tumors (Baker et al., 1990; Wang et al., 1999). Pointcases diagnosed and approximately 14,000 deaths each year
(Greenlee et al., 2000). When diagnosed at an early stage, ovar- mutations at codon 12 of the K-ras gene have been detected
in 30%–50% of mucinous adenocarcinomas and tumors of lowian carcinoma has a survival rate approaching 90%. However,
due to the asymptomatic nature of early stages of the disease, malignant potential, and in 10%–20% of serous adenocarcino-
mas (Mok et al., 1993; Teneriello et al., 1993; Cuatrecasas etmore than two-thirds of cases are not diagnosed until the dis-
ease has spread beyond the ovaries. For these patients, the al., 1997; Caduff et al., 1999; Dokianakis et al., 1999; Morita et
al., 2000; Suzuki et al., 2000). Activation of the phosphatidylino-five-year survival rate is significantly lower. Despite recent ad-
vances in cytoreductive surgery and combination chemother- sitol 3-kinase (PI3-kinase)/Akt pathway has been detected in
several ovarian cancer cell lines and in approximately 30% ofapy, improvement in long-term survival for ovarian cancer pa-
tients has been slight. ovarian cancer specimens (Cheng et al., 1992; Bellacosa et al.,
1995; Shayesteh et al., 1999; Yuan et al., 2000; Sun et al.,The causes of ovarian carcinoma are not known, although
the majority of evidence suggests that reproductive factors and 2001). Most of the evidence that these oncogenes and tumor
suppressor genes are involved in ovarian carcinogenesis isheredity may play roles in the origin of this disease (Holschneider
and Berek, 2000). Studies of human ovarian cancer specimens based on immunohistological examination of tumors. However,
the molecular mechanisms by which these genes contribute tohave revealed several types of genetic alterations. Mutation of
the p53 tumor suppressor gene is the most frequently identified initiation and development of ovarian cancer are still poorly
understood.genetic alteration in serous and poorly differentiated epithelial
ovarian carcinomas, affecting more than 50% of advanced and Advancement in understanding the initiation and progres-
sion of ovarian carcinoma has been slow, mainly due to theearly-stage carcinomas (reviewed in Aunoble et al., 2000). Proto-
S I G N I F I C A N C E
The study of ovarian carcinogenesis has been limited by the lack of appropriate tumor models. We have developed and characterized
a mouse model system for recapitulating human ovarian carcinoma development and progression. The system was designed to
be used for the evaluation of multiple genetic lesions, individually and in combination. We have demonstrated that combinations
of genetic lesions that are commonly present in human ovarian carcinomas can induce ovarian carcinomas in mouse ovarian cells.
Our findings support the theory that the ovarian surface epithelium is the precursor tissue for ovarian carcinomas. We expect that
this model will be useful for studying the basic biology of ovarian carcinoma initiation and progression, identifying markers of
ovarian tumor progression, and establishing parameters for distinguishing a variety of biological behaviors such as metastatic ability,
invasiveness, and sensitivity of ovarian tumors to different therapeutic interventions that target specific molecular pathways altered
in ovarian carcinoma.
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lack of an appropriate experimental model. Even the tissue of the control of tissue-specific promoters (reviewed in Fisher et
al., 1999). Since there are no well-characterized promoters spe-origin in ovarian cancer is not completely understood. Most
human ovarian carcinomas are thought to arise from the ovarian cific for ovary epithelium and stroma, we used transgenic mice
that express TVA in the ovaries and other tissues, and we en-surface epithelium (reviewed in Feeley and Wells, 2001). How-
ever, it is difficult to explain the diversity of ovarian carcinomas sured ovary-specific gene delivery by removing the ovaries from
mice and infecting ovarian cells in vitro (Figure 1). Propagationthat arise from this relatively homogenous tissue. Very little is
known about cellular phenotypic changes in the ovarian surface of ovarian cells in culture facilitated infection by RCAS viruses,
which, like all oncoretroviruses, require a round of cell divisionepithelium as it becomes cancerous or metastatic (Auersperg
et al., 2001). Despite its clinical importance, the biology of this for the integration of viral DNA into the host genome. The ovarian
explants were repeatedly exposed to supernatants from RCAS-tissue is poorly understood, and evidence for its role in ovarian
carcinogenesis is based almost entirely on morphologic and producing cultures of the chicken fibroblast cell line, DF-1 (Himly
et al., 1998; Schaefer-Klein et al., 1998). The stocks of viruseshistologic examination of clinical tumor specimens and immor-
talized ovarian cancer cell lines. carrying different oncogenes or marker genes were added indi-
vidually or in combination, as detailed in the Experimental Proce-The direct progression of benign ovarian lesions to clinical
carcinoma has not been clearly demonstrated for ovarian cancer dures section. The infected ovarian cells were examined in cul-
ture and also reintroduced into recipient mice by subcutaneous(reviewed in Feeley and Wells, 2001). Since early stage malig-
nancy is infrequently detected in patients, the morphologic and or intraperitoneal injection or by transplantation under the ovar-
ian bursa.genetic changes that occur as the benign epithelium becomes
malignant are not well defined. At present, there is little evidence Two TVA transgenic lines were used to develop ovarian
tumor models: a -actin-TVA line (Federspiel et al., 1996) infor a genetic model of multi-step tumor progression in ovarian
cancer, and there is speculation that ovarian carcinoma occurs which the TVA receptor is expressed in all cells in the ovary
under the control of the murine -actin promoter, and a keratinde novo, without any intermediate precursor lesion (Bell and
Scully, 1994). A suitable animal model, in which ovarian cancer 5-TVA line in which expression of the TVA receptor is restricted
to the ovarian surface epithelium (Figure 2A). Since both of thesecould be predictably induced with defined genetic changes,
may be crucial in resolving this controversy. promoters are active in a variety of tissues other than ovarian,
we isolated the ovaries and exposed them to the RCAS virusesHere we report the development of a mouse model for ovar-
ian carcinoma with defined genetic lesions. We used an avian in vitro. To determine the cell type that is receptive to infection
with the RCAS virus, we infected ovarian cells from each lineretroviral gene delivery technique to introduce multiple genetic
lesions in mouse ovarian cells engineered to produce the avian with a viral supernatant carrying DNA encoding the histological
marker gene AP, which we subsequently detected with histo-virus receptor, TVA. Combinations of c-myc, K-ras, and Akt
oncogenes introduced into primary mouse ovarian cells from chemical stain for alkaline phosphatase (Figure 2B). Ovarian
cells cultivated from both transgenic lines are efficiently infectedp53-deficient mice were able to induce phenotypic changes in
mouse ovarian surface epithelial cells in culture and form tumors with RCAS-AP vectors (Figure 2B). All ovarian cells from the
-actin-TVA line can be infected with RCAS-AP. On the otherin vivo, showing that these cells can serve as precursors to
ovarian carcinomas and that the system represents a useful hand, the keratin 5-TVA line has the advantage of allowing infec-
tion only of the cells derived from the surface epithelium of thetool for understanding the molecular basis of ovarian cancer.
ovary, the presumptive precursor of human ovarian carcinoma.
We crossed the TVA transgenic mice with p53/ mice (JacksResults
et al., 1994) to obtain the -actin-TVA/p53/ and the keratin
5-TVA/p53/ lines. The infection efficiency was the same re-Efficient in vitro gene delivery to a restricted subset
of somatic cells in an adult mouse ovary gardless of the p53 status of ovarian cells (data not shown).
We next wanted to determine if infection of ovarian cells withWe used an avian retroviral gene delivery system to introduce
multiple oncogenes and marker genes into the somatic cells of RCAS viruses carrying proto-oncogenes results in detectable
expression of oncoprotein. The ovaries from the -actin-TVA/an adult mouse ovary. This system relies on ectopic expression
of the avian retroviral receptor, TVA, on the surface of mamma- p53/ mice were introduced into culture and infected in vitro
with a combination of RCAS viruses carrying coding sequenceslian cells, and on infection with a replication-competent avian
leukosis virus-derived vector, RCAS (Hughes et al., 1987; Bates for human c-myc (RCAS-c-myc), mouse K-ras with the G12D
activating mutation (RCAS-K-ras), and myristoylated mouseet al., 1993; Young et al., 1993). The presence of the TVA recep-
tor renders mouse cells susceptible to infection with subgroup Akt1 (RCAS-Akt). The expression of c-myc, K-ras, and Akt onco-
proteins in RCAS-infected ovarian cells from -actin-TVA/A RCAS viruses. RCAS vectors can carry coding domains of
oncogenes or marker genes, which are delivered to the TVA p53/ mice was determined by Western blotting (Figure 3) with
receptor-expressing cells upon infection. After entry into mam- antibody against human c-myc and the anti-HA antibody that
malian cells, a newly synthesized DNA copy of the viral genome recognizes the HA tag on the virally introduced Akt and K-ras
integrates into the host DNA, allowing long-term expression of proteins. The level of individual oncoprotein expression did not
the introduced gene. Because mammalian cells do not produce differ if the cells were infected with a single RCAS virus or a
detectable levels of infectious viral particles, avian retroviruses combination of two RCAS viruses (Figure 3).
do not spread to surrounding cells and the receptors on the
cell surface remain unoccupied, allowing repeated infection with Induction of oncogenic lesions in ovarian cells alters
their growth properties in cultureRCAS vectors that can carry different gene inserts.
Tissue specificity of RCAS-mediated delivery is usually ob- We asked if the introduction of c-myc and K-ras into p53/
ovarian cells could induce phenotypic changes in ovarian cellstained by designing transgenic animals that express TVA under
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Figure 1. Strategy for viral gene delivery to ovar-
ian cells in vitro and introduction of infected cells
into recipient mice
Ovaries are isolated from a TVA transgenic
mouse to restrict infection to ovarian cells. DF-1
chicken cells transfected with an RCAS vector
carrying a gene of interest are used to obtain
high titer virus stock. In vitro propagation of pri-
mary ovarian cells facilitates multiple rounds of
infection with a combination of RCAS viruses car-
rying different oncogenes and marker genes.
After several days of infection in vitro, ovarian
cells are aggregated and implanted into recipi-
ent mice.
in culture (Figure 4). We first compared in vitro growth character- representative cross-sections of the cell cultures indicate that
the cells that were infected with RCAS viruses carrying onco-istics of ovarian cells from -actin-TVA/p53/ mice that were
infected with RCAS-c-myc or RCAS-K-ras, or with a combina- genes grow in multiple layers (Figure 4C).
tion of the two viruses. The number of cells in individual cultures
was followed for 8 days (Figure 4A). Infection of ovarian cells Tumor induction in ovarian cells requires a combination
of several genetic changeswith RCAS-K-ras or with RCAS-c-myc increased their prolifera-
tion rate in comparison to the ovarian cells infected with RCAS- Mutation or overexpression of genes such as p53, c-myc, K-ras
and Akt are frequently detected in human ovarian carcinomaAP. However, the proliferation rate increased even more dramat-
ically when ovarian cells were infected with the combination of specimens (Aunoble et al., 2000), although it is not known
whether these genetic changes must occur in combination toRCAS-K-ras and RCAS-c-myc.
To examine the cellular responses to oncogenic lesions in induce tumor growth. Therefore, we asked how many genetic
changes are necessary to induce ovarian carcinoma in mouseprimary ovarian cells in culture, we visually examined the ap-
pearance of cell cultures on day 6. The majority of cells that were ovarian cells. Ovarian cells from -actin-TVA/p53/, -actin-
TVA/p53/, keratin 5-TVA/p53/, and keratin 5-TVA/p53/infected with RCAS-AP acquired features of normal terminal
differentiation, such as enlarged cells with flat morphology (Fig- mice were propagated in culture for 7 days, during which they
were infected with RCAS-c-myc, RCAS-K-ras and RCAS-Akture 4B). A subset of cells in the ovarian cultures that were
infected with RCAS-K-ras or RCAS-c-myc viruses continued to viruses, individually or in various combinations. After infection,
ovarian cells were trypsinized and 105 or 106 cells were injectedproliferate. The epithelial-to-stromal cell ratio increased in these
cultures as judged by the cobblestone appearance of the prolif- subcutaneously into nude mice, and the mice were examined
regularly for tumor formation (Table 1). No tumors were pro-erating cells. The proliferation of the epithelial cell population
was most prominent in cultures infected with the combination duced from ovarian cells infected with an RCAS vector carrying
an AP marker gene or only one oncogene (c-myc, K-ras or Akt),of RCAS viruses carrying c-myc and K-ras (Figure 4B). The
Figure 2. Expression of TVA and susceptibility of
ovarian cells from TVA transgenic mice to RCAS
infection
A: Immunohistochemical detection of the TVA
receptor with the TVA antibody. Ovaries isolated
from -actin-TVA transgenic mice express the
TVA receptor in both stromal cells and the ovar-
ian surface epithelium. In ovaries isolated from
keratin 5-TVA transgenic mice, expression of the
TVA receptor is restricted to the cells of the ovar-
ian surface epithelium.
B: Detection of RCAS-AP-infected cells by AP
color reaction. Ovarian cells from each trans-
genic line were infected with the RCAS-AP virus
in culture. Endogenous AP was heat-inactivated,
and the infected cells that produce AP were
detected by the AP color reaction. Both stromal
and epithelial cells from -actin-TVA ovaries are
susceptible to RCAS-AP infection. In ovaries from
keratin 5-TVA mice, only the ovarian surface epi-
thelial cells are susceptible to RCAS-AP infection,
while stromal cells are AP-negative.
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Table 1. Combinations of changes in oncogenes and tumor suppressor
genes required for tumor formation by mouse ovarian cells injected subcu-
taneously into nude mice
TVA p53 Oncogene
transgenic background combination Tumor
wt AP marker 
wt c-myc 
wt K-ras 
wt Akt 
-actin-TVA
wt c-myc  K-ras 
ovarian cells
wt K-ras  Akt 
wt Akt  c-myc 
wt Akt  c-myc  K-ras 
or
p53/ AP marker 
p53/ c-myc 
p53/ K-ras 
keratin 5-TVA
p53/ Akt 
ovarian cells
p53/ c-myc  K-ras 
p53/ K-ras  Akt 
p53/ Akt  c-myc 
p53/ Akt  c-myc  K-ras 
Ovaries from -actin-TVA or from keratin 5-TVA mice, in wild type or p53/
backgrounds, were isolated and infected in vitro with RCAS vectors carrying
Figure 3. Expression of oncogenic proteins in ovarian cells after in vitro infec- AP, c-myc, K-ras, or Akt, individually or in combination. 105 or 106 cells were
tion with RCAS viruses injected subcutaneously into nude mice. Mice were observed weekly for
tumor growth for 8 weeks. Tumors that reached 1 cm in diameter wereWestern blot of -actin-TVA/p53/ ovarian cells infected with RCAS viruses
counted as positive. At least two nude mice were injected with ovariancarrying AP, c-myc, K-ras, or Akt, individually or in combinations of two RCAS
cells that were infected with each combination of viruses, and the experi-viruses. The same amount of cell lysate was loaded into each lane. HA-
ment was done at least twice with each combination.tagged Akt and K-ras proteins were detected with the anti-HA probe. The
expression of c-myc was determined with an antibody against human
c-myc.
epithelial sheets and stromal cells (Figure 5). Staining with the
antibody against TVA (Figure 5A) revealed that the epithelialregardless of the p53 status or the promoter driving the TVA
sheets in the tumor were derived from the ovarian surface epi-transgene. Ovarian cells from mice that were wild-type for the
thelium since TVA is present exclusively in the ovarian surfacep53 gene did not produce tumors even when transduced with
epithelium in the keratin 5-TVA ovaries (Figure 5A, inset). Theany combination of two or all three oncogenes. However, ovar-
identity and epithelial characteristics of these cells were con-ian cells from p53/ mice resulted in tumors when transduced
firmed with the TROMA-1 antibody (Figure 5B) which specificallywith any combination of two or three oncogenes, regardless of
labels the cells of the ovarian surface epithelium by recognizingwhether the cells were derived from -actin-TVA or keratin 5-
Keratin 8 (Figure 5B, inset). The same cells in the tumor wereTVA mice. Therefore, genetic changes in the p53 tumor suppres-
reactive to an antibody that recognizes the HA epitope tag onsor gene and at least two oncogenes (c-myc and K-ras, K-ras
the Akt protein (Figure 5C) which was expressed in tumor cellsand Akt, or Akt and c-myc) are required to induce tumors in
as a result of infection with the RCAS-Akt virus. The HA epitope,ovarian cells in this assay (Table 1).
as expected, is not present in the uninfected ovary (Figure 5C,Although individual genetic lesions in ovarian cells are not
inset). From these results, we concluded that the epithelial com-sufficient for tumor formation, they may induce changes that
ponent of the tumor is derived from the surface epithelial cellspredispose to tumor development. We monitored the mice for
of the ovary from the keratin 5-TVA transgenic mouse. Thetumor formation for six months to allow development of slow-
stromal component of the tumor could represent either cellsgrowing tumors, or tumors that require secondary mutations.
recruited from the nude mouse subcutaneous stroma or theOvarian cells from -actin-TVA/p53/ and keratin 5-TVA/
residual stromal cells from the keratin 5-TVA transgenic ovary.p53/ mice that were infected with only one RCAS virus stock
The origin of the stromal component of the tumor can becarrying c-myc, K-ras, or Akt, developed tumors with latency
more accurately determined in the subcutaneous tumors de-varying from 12 weeks to 6 months (data not shown). Thus,
rived from the -actin-TVA ovaries. In ovaries from the -actin-ovarian cells with genetic changes that predispose to tumor
TVA mice, both ovarian surface epithelium and the ovariandevelopment most likely acquire additional changes with time.
stroma can be labeled with the antibody against TVA (Figure
5D, inset). However, the stromal cells in the tumor were notOvarian surface epithelium is the precursor tissue
reactive with the antibody against TVA, indicating that they werefor ovarian epithelial cancer
not derived from the -actin-TVA ovary (Figure 5D). Instead, theMost human ovarian tumors are believed to arise from the single
stromal cells must have been recruited from the nude mouselayer of epithelial cells that covers the ovarian surface. We used
stroma. Since all cells in the -actin-TVA ovaries are susceptiblehistological markers to determine the tissue of origin for the
to infection with viruses (Figure 2), it might have been expectedtumors that developed after subcutaneous injection of infected
that the tumors would be derived from the surface epithelialovarian cells into nude mice. Subcutaneous tumors derived
from keratin 5-TVA ovaries consisted mostly of undifferentiated cells as well as from the cells of the ovarian stroma. Remarkably,
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Figure 4. Oncogenic c-myc and K-ras collabo-
rate in inducing proliferation of epithelial ovarian
cells
A: Proliferation curves of ovarian cells from -
actin-TVA/p53/ mice that were infected with
RCAS viruses carrying AP, c-myc, K-ras, or with a
combination of RCAS viruses carrying c-myc and
K-ras. Five days after infection with RCAS viruses,
each culture of the virally infected cells was split
into 12 separate cultures that were maintained
for 8 days. The cell proliferation rates were deter-
mined by fixing triplicate cultures every 2 days,
staining them with crystal violet dye, and mea-
suring the light absorbance of the extracted dye
at 590 nm. This procedure allowed us to count
the proliferating cells, as well as the viable termi-
nally differentiated cells that would normally be
lost if the cells were continually passaged. Prolif-
eration curves were plotted as a ratio of the light
absorbance and the time. The error bars indicate
the extreme values of light absorbance in three
separate cultures. Proliferation of ovarian cells
from -actin-TVA/p53/ mice was induced by
oncogenic change in either c-myc or K-ras, but
the effect was further amplified in ovarian cells
with genetic changes in both genes.
B: Morphological appearance of the cell popu-
lations described in A at day 6. Cultured ovarian
cells infected with RCAS-AP acquire features
of normal terminal differentiation and senes-
cence. Introduction of oncogenic lesions in-
duces marked changes to ovarian cell mor-
phology and differentiation, which is especially
pronounced in the ovarian epithelial cells.
C: Representative cross-sections of ovarian cell
populations in B.
only ovarian epithelial cells gave rise to the tumors as deter- pancreas, kidneys (Figure 6C, arrows), mesothelial lining of the
peritoneum, omentum, and the diaphragm (not shown). Mostmined by staining with the TROMA-1 antibody (Figures 5E and
5E, inset). of the metastases grew on the surfaces of organs (Figure 6D,
arrows), but some penetrated deep into the tissue as illustrated
with sections of liver and spleen that were immunostained withOvarian tumors induced in the mouse model resemble
the antibody against the TVA receptor (Figure 6D, arrowheads).development and metastatic spread of human
The induced tumors were histologically diagnosed as carci-ovarian carcinoma
nomas. Primary ovarian tumors consisted mostly of sheets ofThe subcutaneous tumor model in nude mice was convenient
poorly differentiated epithelial cells (data not shown). The metas-to use as a rapid method to determine the genetic changes
tases ranged from sheets of poorly differentiated cells (notthat are necessary for the induction of tumors in ovarian cells.
shown) to organized papillary projections (Figure 6E) that resem-However, ovarian tumors develop in the peritoneal cavity and
ble ovarian papillary serous carcinoma.rarely spread outside the peritoneum. In order to monitor ovarian
tumor development in its natural environment, we developed a
technique for implanting in vitro-infected ovarian cells into their Induction of ovarian carcinoma
in immunocompetent miceorthotopic site, under the ovarian bursa (Experimental Proce-
dures section). Ovarian cells isolated from -actin-TVA/p53/ The immune system has been shown to play a role in cancer
development in mice (Shankaran et al., 2001). Thus, nude micemice or from keratin 5-TVA/p53/ mice were infected in culture
with RCAS viruses and implanted under the ovarian bursa of may not be the ideal model system in which to study ovarian
cancer development and metastatic spread. We attempted tothe left ovary of a nude mouse. The first sign of tumor develop-
ment was a palpable solid tumor of the left ovary. The tumor induce ovarian tumors in immunocompetent mice by implanting
RCAS-infected ovarian cells under the ovarian bursa. Ovarianwas confined to the ovary in mice that were sacrificed within
the first 2 weeks of ovarian cell implantation (data not shown). cells from the -actin-TVA/p53/ mouse or from the keratin
5-TVA/p53/ mouse were infected in vitro with a combinationIntraperitoneal tumor growths at other sites were palpable within
4 weeks after detection of primary tumor. Metastatic spread of RCAS viruses carrying c-myc, K-ras, and Akt. The cells were
then implanted under the ovarian bursa of the contralateral ovarywas indicated by abdominal bloating and the presence of bloody
ascites (Figure 6A). The tumors spread from the left ovary to of the same mouse. Ovarian tumors developed at the implanted
site in both keratin 5-TVA/p53/ mice, and in -actin-TVA/the intraperitoneal and retroperitoneal organs (Figure 6B). Meta-
static sites included the contralateral ovary, intestines, liver, p53/ mice (Figure 7A and data not shown) three months after
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Figure 5. Ovarian surface epithelium is the pre-
cursor tissue for ovarian carcinoma
A–C: Sections of a subcutaneous tumor in a nude
mouse derived from the keratin 5-TVA/p53/
ovarian cells infected with a combination of
RCAS-c-myc and RCAS-Akt viruses. The consecu-
tive sections were probed with antibodies that
recognize TVA, Keratin 8 and the HA-tagged Akt
protein. Insets show a normal ovary from an unin-
fected keratin 5-TVA mouse probed with the
same antibodies. A: The TVA-positive cells in the
tumor originate from the ovarian surface epithe-
lium because this is the only cell type that ex-
presses TVA in the ovaries from keratin 5-TVA
transgenic mice (A, inset). B: The same TVA-posi-
tive cells in the tumor are also positive for the
Keratin 8 marker, indicating that they maintain
their epithelial characteristics and resemble the
Keratin 8-positive cells of the ovarian surface epi-
thelium (B, inset). C: The TVA-positive cells in the
tumor also express virally introduced Akt onco-
gene. The HA-tagged Akt is not present in the
uninfected ovary (C, inset).
D and E: Consecutive sections of a subcutaneous
tumor in a nude mouse derived from the -actin-
TVA/p53/ ovarian cells infected with a combi-
nation of RCAS-c-myc and RCAS-K-ras viruses.
The sections were probed with antibodies that
recognize TVA receptor and Keratin 8. Insets
show a normal ovary from uninfected -actin-
TVA mouse probed with the same antibodies as
the tumor sections. D: The tumor consists of TVA-
positive and TVA-negative cells. The TVA-positive cells originate from the ovary of the -actin-TVA transgenic mouse (D, inset). Since all cells from -actin-
TVA ovaries express TVA, the TVA-negative stromal cells in the tumor must be recruited from the host tissue and not from ovarian stroma. E: The TVA-positive
cells in the tumor are epithelial as determined by the expression of the Keratin 8 marker which is present exclusively in the epithelial cells in the ovary (E,
inset). Each bar represents 50 m.
implantation of the ovarian cells. The histological appearance (Federspiel et al., 1996) were used to infect both ovarian epithe-
lium and stroma, while keratin 5-TVA mice were used to restrictof ovarian tumors induced in immunocompetent mice (Figure
7B) resembled that of undifferentiated epithelial tumors. the infection to the cells of the ovarian surface epithelium. The
major drawback of this system is the necessity for propagation
of ovarian cells in culture in order to assure efficient infectionDiscussion
with multiple RCAS vectors. However, since the cells are propa-
gated in culture for only a short period of time it is unlikely thatOur goal was to develop a suitable system for recapitulating
human ovarian carcinoma development and progression. The spontaneous mutations would occur. Another deviation from
naturally occurring tumors that arise through clonal expansion issystem was designed such that tumors are induced in adult
animals, similar to the occurrence in the majority of naturally that multiple cells in this system are potential tumor precursors.
Although there is an experimental advantage to inducing rapiddeveloping human tumors. Furthermore, the system was de-
signed to be used for the evaluation of multiple genetic lesions, tumor proliferation in a large number of cells with the same
genetic lesions, this system does not entirely reflect the naturalindividually and in combination thus increasing the ability to
simulate a wide spectrum of human ovarian tumors without development of tumors.
Ovarian carcinomas are thought to arise from the epithelialextensive breeding protocols.
We used the TVA receptor-dependent avian RCAS retroviral lining that covers the surface of the ovary. Alternatively, ovarian
carcinomas may arise from other cell types within the ovary, ordelivery technique to introduce defined multiple genetic lesions
into mouse ovarian cells. This delivery technique has recently from the components of the secondary Mu¨llerian system that
are not part of the ovary (Dubeau, 1999). Our mouse modelbeen adapted for transferring genes into specific mouse cells
from transgenic mice programmed to express the avian TVA system is well suited to identify the tissue of origin for the ovarian
carcinomas we study. First, we were able to induce geneticreceptor in various tissues (Federspiel et al., 1994, 1996; Holland
et al., 1998, 2000; Holland and Varmus, 1998; Doetsch et al., lesions in isolated ovaries, thus ensuring that only ovarian cells
contribute to tumor formation in our model. Second, we were1999; Murphy and Leavitt, 1999). We demonstrated that the
RCAS-TVA system allows efficient gene transfer to cultured able to use the keratin 5-TVA system to induce oncogenic
changes specifically in the cells of the ovarian surface epithe-primary ovarian cells. The genes can be transduced to ovarian
cells individually or in combination. The ovarian cells that are lium. Using the TVA receptor as a marker for the ovarian surface
epithelial cells, we have demonstrated that the ovarian tumorssusceptible to infection with RCAS viruses can be limited by
cell-specific expression of the TVA receptor. -actin-TVA mice in the keratin 5-TVA model system arise from the ovarian surface
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Figure 6. Intraperitoneal tumor spread in nude
mice after implantation of ovarian cells with in-
duced genetic lesions under the ovarian bursa
A–E: Tumors derived from -actin-TVA/p53/
ovarian cells that were infected with a combina-
tion of RCAS viruses carrying c-myc and K-ras
oncogenes and implanted under the ovarian
bursa of a nude mouse. A: Abdominal bloating
and the presence of bloody ascites were the
typical signs of the intraperitoneal tumor spread.
B: Ovarian tumor spread in the peritoneal cavity.
C: Ovarian tumor spread to the intraperitoneal
and retroperitoneal organs. Arrows indicate
ovarian tumor spread to the spleen, liver, intes-
tine, kidney, and the contralateral ovary. D: Sec-
tions of the liver and the spleen probed with anti-
body against TVA to identify the ovarian tumor
cell metastases. The tumor cells metastasize to
the surfaces of organs (arrows) and deep into
the tissue (arrowheads). E: Papillary organization
of metastatic ovarian tumor resembles ovarian
papillary carcinoma.
epithelial cells. Surprisingly, ovarian stromal cells that were oncogenes into cells from p53/ and p53/ mice in an attempt
to model the genetic aberrations that characterize many humantransduced with oncogenes after infection of cells from -actin-
ovarian carcinomas. A combination of three oncogenes (c-myc,TVA transgenic mice did not contribute to the tumor (Figures
K-ras, and Akt) is not sufficient to induce a tumorigenic state5D and 5E). There has been much speculation as to why the
in ovarian cells from p53/ mice, indicating the importance ofsurface epithelial cells are the ovarian cells that most frequently
the p53 lesion. Our results suggest that the absence of p53give rise to ovarian tumors (Auersperg et al., 2001). Our results
predisposes ovarian epithelial cells to tumor formation while inwith cells propagated in vitro indicate that p53/ovarian epithe-
the presence of another initiating event, such as a growth signallial cells proliferate more slowly than stromal cells. However, in
produced by a mutant or an overexpressed oncogene. We de-the presence of oncogenic lesions, the proliferation of epithelial
termined that at least two oncogenic changes are required forcells is more rapid than the proliferation of stromal cells. It is
rapid tumor formation in the p53-deficient ovarian cells (Tablepossible that the combination of oncogenic lesions that we used
1). Our preliminary results suggest that deletion of other tumorin this study specifically induces tumorigenic changes in the
suppressor genes, such as INK4a/ARF, also contribute to ovar-
surface epithelial cells and not in the cells of the ovarian stroma.
ian tumor development when combined with oncogenic lesions
Because some residual epithelial components of the secondary in c-myc, K-ras, or Akt (S.O., unpublished). Thus, the necessity
Mu¨llerian system may exist within the ovarian hilum and medulla for a proliferative signal balanced with an anti-apoptotic signal
(Dubeau, 1999), we cannot completely rule out the possibility may be a prerequisite for tumor formation in the ovarian cells.
that the tumors in mice are derived from the secondary Mu¨llerian Although changes in the function of p53 are commonly seen
epithelium instead of the ovarian surface epithelium. However, in ovarian carcinomas, patients with Li-Fraumeni syndrome
this is very unlikely since the oncogene-induced proliferation of rarely develop ovarian carcinomas, suggesting that a mutation
the morphologically distinct ovarian surface epithelial cells is in p53 is probably an essential step in ovarian carcinogenesis,
already apparent in vitro. but not the initial event. Although we have not addressed the
Several studies indicate that ovarian tumors are the end temporal sequence of genetic events in ovarian carcinoma initia-
result of a complex pathway involving multiple oncogenes and tion and progression, the retroviral gene delivery system allows
tumor suppressor genes, which include c-myc, K-ras, Akt, Her- for multiple sequential infections with different RCAS vectors.
2/neu, p53, and BRCA1/2 (reviewed in Gallion et al., 1995; Thus, multiple oncogenes, dominant-negative tumor suppres-
Berchuck and Carney, 1997; Lynch et al., 1998; Aunoble et sor genes, or the gene encoding the Cre recombinase, could
be sequentially introduced into ovarian cells. Additionally, theal., 2000). In our study, we introduced c-myc, K-ras and Akt
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mice to obtain TVA/p53/ mice. The resulting crosses were on a mixed
genetic background. Genotypes were determined by PCR with tail DNA.
Viral constructs and virus production
RCAS-AP encodes the heat-resistant placental alkaline phosphatase (Hol-
land and Varmus, 1998). RCAS-K-ras carries the mutant G12D activated
K-ras insert obtained from Dave Tuveson and Tyler Jacks, MIT (Johnson et
al., 2001). RCAS-Akt carries myristoylated and HA-tagged mouse Akt1 that
is constitutively activated. RCAS-c-myc carries the human c-myc (obtained
from Brian Lewis, MSKCC). The DF-1 cell line, an immortalized line of chicken
cells (Himly et al., 1998; Schaefer-Klein et al., 1998), was used for the
production of viruses. The cells were grown in Dulbecco’s Modified Eagle
Medium (DMEM) supplemented with 10% fetal calf serum (FCS), 0.2 mM
L-glutamine and 1% penicillin/streptomycin. Plasmid forms of RCAS vectors
were transfected into DF-1 cells, resulting in viral spread and high titer
production of viruses. Viral supernatant was passed through an 0.8 m
syringe filter to obtain cell-free viruses for ovarian cell infection.
Ovary isolation
Three- to five-week-old female mice were anesthetized with Avertin and the
right ovary was isolated using standard aseptic surgical procedures. TheFigure 7. Ovarian tumor induction in immunocompetent mice
ovarian bursa was cut with microsurgical scissors and pushed aside toA: Ovarian cells from the right ovary of the -actin-TVA/p53/ mouse were
expose the ovarian surface. The ovary was separated from the bursa andtransduced with c-myc, K-ras, and Akt oncogenes and implanted under
transferred to a tissue culture dish containing DMEM.the ovarian bursa of the left ovary. The arrow points to the tumor that
developed in the left ovary three months after intrabursal implantation of
Growth of ovary explants, infection of ovarian cells in culture,the RCAS-infected ovarian cells. B: H&E staining of the tumor section reveals
and ovarian cell aggregationan undifferentiated epithelial neoplasm, arranged in nests.
Each ovary was cut into 5–10 pieces and the explants were allowed to grow
in a CO2 incubator for 48 hr to allow for cell attachment and growth. The
medium was then replaced with fresh viral supernatant every 12 hr for 5
days. The transduced explants at day 7 were washed with Phosphate Bufferuse of inducible promoters in the RCAS system could provide
Saline (PBS), trypsinized, and briefly centrifuged to obtain a tight aggregate
the means to study the dependence of tumor growth on sus- of cells.
tained production of a tumor-inducing oncogene.
Thus far, we have employed this model system to improve Ovary implantation
Prior to ovary implantation, the intact ovary on the left side was exposedour understanding of the genetic changes leading to the initia-
as described above. The bursa was opened with microsurgical scissors attion of ovarian cancer and to identify cooperating events in
one end, keeping most of the membrane intact, and the entire ovary wasmalignancy by using several different combinations of genes
removed. While holding the bursa open with tweezers, the replacementthat are thought to contribute to cancer development. Unlike
ovarian cell aggregate was pushed into the bursa. A very small amount of
other existing mouse models that utilize mouse ovarian cell lines surgical glue was applied to close the bursa and to keep the ovarian cell
that are spontaneously transformed during prolonged growth aggregate in place. The implanted ovary was placed inside the body wall
in culture (Adams and Auersperg, 1981; Kido and Shibuya, 1998; and the skin was closed with wound clips.
Roby et al., 2000), our model system uses genetically defined
Ovarian cell injection into micecombinations of lesions. We have focused on p53, c-myc, K-ras,
Infected ovarian cells were washed three times in PBS, trypsinized, andand Akt genes because lesions in these genes are commonly
collected by brief centrifugation. The pelleted cells were washed in PBS.present in human ovarian carcinoma samples. However, we
The mice were injected subcutaneously with 105 or 106 cells in a 100–200
have not tested other genes, such as HER-2/neu, FGFs, TGF-,
l volume of PBS.
met, and BRCA 1 and 2, that have been shown to play a role
in ovarian tumorigenesis. The system that we established can Alkaline phosphatase (AP) staining
also be used to test the oncogenic potential of many other The AP was detected as described (Holland et al., 1998) with minor modifica-
tions. Briefly, cells infected with RCAS-AP were washed two times with PBS,genes, in order to identify those that might contribute to the
fixed with methanol for 5 min, and washed three times with PBS. AP bufferinitiation and progression of ovarian cancer.
(100 mM Tris, pH 9.5; 100 mM NaCl; 50 mM MgCl2) was added to the cells.
Endogenous AP was heat-inactivated by floating the Petri dish in a waterExperimental procedures
bath at 65C for 45 min. After cooling the cells to room temperature, the AP
buffer was replaced with the AP staining solution (5 ml AP buffer; 100 l ofMouse strains
100 mM levamisole; 10 l BCIP; 10 l NBT). The reaction was left to develop-actin-TVA mice (Federspiel et al., 1996) and p53/ mice (Jacks et al.,
overnight in the dark and stopped the next morning by rinsing out the staining1994) have been described. For the generation of keratin 5-TVA mice, a
solution with distilled water.bluescript KS() plasmid containing a 5.2 kb fragment of the bovine keratin
5 promoter, a 0.6 kb fragment of the rabbit -globin intron, a polylinker
Determining efficiency of in vitro infection with RCAS-APincluding a NheI site which was replaced for a NotI site, and a 3 poly A
Ovarian cells from the-actin-TVA line or the keratin 5-TVA line were exposedsequence (Ramirez et al., 1994) were used to insert the pg800 tva cDNA
to fresh viral supernatant twice a day for 5 days. After development of AP(Bates et al., 1993) as a NotI fragment. The transgene was isolated after
color reaction, four representative frames were photographed and the AP-digestion by SalI. Transgenic mice were generated in FVB/N mice using
positive and AP-negative cells were counted in all four photographs. Surfacestandard techniques, and identified by Southern blot using the tva cDNA as
epithelial cells were recognizable by their tightly packed cobblestone appear-a probe. The female nude mice (nu/nu) were purchased from the Charles
River Laboratories. The TVA transgenic mice were crossed with the p53/ ance; all other cell types were counted as stromal cells.
60 CANCER CELL : FEBRUARY 2002
A R T I C L E
ReferencesMeasurement of cell proliferation
Ovaries from 12 -actin-TVA/p53/ mice were isolated and transferred into
culture. The ovarian explants were replated two times to obtain a homoge- Adams, A.T., and Auersperg, N. (1981). Transformation of cultured rat ovarian
nous culture of ovarian cells. The cells were then split into four separate surface epithelial cells by Kirsten murine sarcoma virus. Cancer Res. 41,
2063–2072.cultures and each culture was infected with viruses carrying the following
genes: AP, c-myc, K-ras, or a combination of c-myc and K-ras. After 5 days Auersperg, N., Wong, A.S., Choi, K.C., Kang, S.K., and Leung, P.C. (2001).
of infection with viruses, each culture was separated into 12 cultures in a Ovarian surface epithelium: biology, endocrinology, and pathology. Endocr.
six-well dish, 1  103 cells per well. In order to monitor cell proliferation, Rev. 22, 255–288.
triplicate cultures from each viral infection were sacrificed every second day.
Aunoble, B., Sanches, R., Didier, E., and Bignon, Y.J. (2000). Major onco-The cells were fixed with 10% buffered formalin, rinsed with water, and
genes and tumor suppressor genes involved in epithelial ovarian cancerstained with a 0.1% solution of crystal violet (Sigma) for 6 hr. The cells were
(review). Int. J. Oncol. 16, 567–576.
then washed extensively under running water and dried. Cell-associated
Baker, V.V., Borst, M.P., Dixon, D., Hatch, K.D., Shingleton, H.M., and Miller,dye was extracted with 2 ml of acetic acid. The aliquots were diluted 1:4
D. (1990). c-myc amplification in ovarian cancer. Gynecol. Oncol. 38, 340–with water, and the optical density was determined at 590 nm.
342.
Western blot analysis Bates, P., Young, J.A., and Varmus, H.E. (1993). A receptor for subgroup A
Rous sarcoma virus is related to the low density lipoprotein receptor. CellCells were lysed with PBS containing 0.1% Triton X-100 and a protease
74, 1043–1051.inhibitor mix (CompleteTM, Boehringer Mannheim), scraped from the culture
dish, and cleared with centrifugation in a microfuge for 5 min at 4C. Equal Bell, D.A., and Scully, R.E. (1994). Early de novo ovarian carcinoma. A study
amounts of total cell protein were boiled in Laemmli buffer for 5 min, sepa- of fourteen cases. Cancer 73, 1859–1864.
rated by 10% SDS-polyacrylamide gel and transferred to nitrocellulose.
Bellacosa, A., de Feo, D., Godwin, A.K., Bell, D.W., Cheng, J.Q., Altomare,Filters were blocked for 1 hr at room temperature in 5% dry milk in Tris
D.A., Wan, M., Dubeau, L., Scambia, G., and Masciullo, V. (1995). MolecularBuffered Saline 0.1% TritonX-100 (TBST), washed in TBST, and incubated
alterations of the AKT2 oncogene in ovarian and breast carcinomas. Int. J.
with primary antibodies in 5% dry milk in TBST at 4C overnight. Anti-human
Cancer 64, 280–285.
c-myc (9E10; Santa Cruz) and anti-HA probe (Y-11; Santa Cruz), were used
Berchuck, A., and Carney, M. (1997). Human ovarian cancer of the surfaceat a 1:100 dilution. After several washes, secondary peroxidase conjugated
epithelium. Biochem. Pharmacol. 54, 541–544.antibodies (Boehringer) were used at a 1:5,000 dilution. The membrane
was washed in TBST and the proteins were detected using an enhanced Brulet, P., Babinet, C., Kemler, R., and Jacob, F. (1980). Monoclonal antibod-
chemiluminescence (ECL) detection system (Amersham) following the manu- ies against trophectoderm-specific markers during mouse blastocyst forma-
facturer’s recommendation. tion. Proc. Natl. Acad. Sci. USA 77, 4113–4117.
Caduff, R.F., Svoboda-Newman, S.M., Ferguson, A.W., Johnston, C.M., and
Immunohistochemistry Frank, T.S. (1999). Comparison of mutations of Ki-RAS and p53 immunoreac-
Tissues and ovarian cells grown on Millipore filters were fixed in Carnoy’s tivity in borderline and malignant epithelial ovarian tumors. Am. J. Surg.
fixative (absolute ethanol: chloroform: acetic acid; 6:3:1) for 6 hr at 4C, after Pathol. 23, 323–328.
which they were transferred to 70% ethanol and embedded in paraffin.
Cheng, J.Q., Godwin, A.K., Bellacosa, A., Taguchi, T., Franke, T.F., Hamilton,
Paraffin-embedded sections were cleared in a graded xylene/ethanol series
T.C., Tsichlis, P.N., and Testa, J.R. (1992). AKT2, a putative oncogene encod-
and used for immunohistochemistry with an ABC antibody staining kit (Vector ing a member of a subfamily of protein-serine/threonine kinases, is amplified
Laboratories) according to manufacturer’s instructions. After color develop- in human ovarian carcinomas. Proc. Natl. Acad. Sci. USA 89, 9267–9271.
ment, slides were counterstained with hematoxylin (Sigma) and mounted
Cuatrecasas, M., Villanueva, A., Matias-Guiu, X., and Prat, J. (1997). K-raswith water-based mounting medium (Triangle Biomedical Sciences). Partially
mutations in mucinous ovarian tumors: a clinicopathologic and molecularpurified supernatant of TROMA-1 antibody (Brulet et al., 1980) was obtained
study of 95 cases. Cancer 79, 1581–1586.
from the Developmental Studies Hybridoma Bank at The University of Iowa
Doetsch, F., Caille, I., Lim, D.A., Garcia-Verdugo, J.M., and Alvarez-Buylla,and used at a 1:25 dilution. Affinity-purified rabbit polyclonal anti-TVA anti-
A. (1999). Subventricular zone astrocytes are neural stem cells in the adultbody (Bates et al., 1993) was obtained from Andrew Leavitt (UCSF) and
mammalian brain. Cell 97, 703–716.used at a concentration of 1 g/ml. Anti-HA antibody (Y-11) was used at a
concentration of 2 g/ml. Dokianakis, D.N., Varras, M.N., Papaefthimiou, M., Apostolopoulou, J., Simi-
akaki, H., Diakomanolis, E., and Spandidos, D.A. (1999). Ras gene activation
in malignant cells of human ovarian carcinoma peritoneal fluids. Clin. Exp.Acknowledgments
Metastasis 17, 293–297.
We thank Steve Hughes (FCRC, NCI, NIH) for the -actin-TVA mice; Doug Dubeau, L. (1999). The cell of origin of ovarian epithelial tumors and the
Foster for the DF-1 cells; Brian Lewis (MSKCC) for the human c-myc cDNA; ovarian surface epithelium dogma: does the emperor have no clothes? Gyne-
Alfonso Bellacosa (FCCC) for the Akt1 insert; Eric Holland (MSKCC) for the col. Oncol. 72, 437–442.
RCAS-AP vector; Dave Tuveson and Tyler Jacks (MIT) for the mutant K-ras
Federspiel, M.J., Bates, P., Young, J.A., Varmus, H.E., and Hughes, S.H.cDNA; Andrew Leavitt (UCSF) for the TVA antibody; Galen Fisher for the
(1994). A system for tissue-specific gene targeting: transgenic mice suscepti-
HA-tagged K-ras virus; Jennifer Doherty for mouse genotyping and immuno- ble to subgroup A avian leukosis virus-based retroviral vectors. Proc. Natl.
histochemical staining; Amy Chen (NHGRI, NIH) for the initial assistance Acad. Sci. USA 91, 11241–11245.
with survival surgery; Wendy Hively, Jennifer Doherty, and Mary Barrett for
Federspiel, M.J., Swing, D.A., Eagleson, B., Reid, S.W., and Hughes, S.H.technical assistance and mouse husbandry; Kristy Daniels for assistance in
(1996). Expression of transduced genes in mice generated by infecting blas-preparation of the manuscript; David Spriggs, Jeff Boyd, and members of
tocysts with avian leukosis virus-based retroviral vectors. Proc. Natl. Acad.the Varmus lab for useful discussions. This work was supported by the
Sci. USA 93, 4931–4936.
Susan G. Komen Fellowship to S.O. and the Department of Defense Breast
Feeley, K.M., and Wells, M. (2001). Precursor lesions of ovarian epithelialCancer Fellowship to Y.L.
malignancy. Histopathology 38, 87–95.
Fisher, G.H., Orsulic, S., Holland, E., Hively, W.P., Li, Y., Lewis, B.C., Williams,
B.O., and Varmus, H.E. (1999). Development of a flexible and specific gene
Received: August 14, 2001 delivery system for production of murine tumor models. Oncogene 18, 5253–
5260.Revised: October 23, 2001
CANCER CELL : FEBRUARY 2002 61
A R T I C L E
Gallion, H.H., Pieretti, M., DePriest, P.D., and van Nagell, J.R. (1995). The Murphy, G.J., and Leavitt, A.D. (1999). A model for studying megakaryocyte
development and biology. Proc. Natl. Acad. Sci. USA 96, 3065–3070.molecular basis of ovarian cancer. Cancer 76, 1992–1997.
Greenlee, R.T., Murray, T., Bolden, S., and Wingo, P.A. (2000). Cancer statis- Ramirez, A., Bravo, A., Jorcano, J.L., and Vidal, M. (1994). Sequences 5 of
tics, 2000. CA Cancer J. Clin. 50, 7–33. the bovine keratin 5 gene direct tissue- and cell-type-specific expression of
a lacZ gene in the adult and during development. Differentiation 58, 53–64.
Himly, M., Foster, D.N., Bottoli, I., Iacovoni, J.S., and Vogt, P.K. (1998).
The DF-1 chicken fibroblast cell line: transformation induced by diverse Roby, K.F., Taylor, C.C., Sweetwood, J.P., Cheng, Y., Pace, J.L., Tawfik,
oncogenes and cell death resulting from infection by avian leukosis viruses. O., Persons, D.L., Smith, P.G., and Terranova, P.F. (2000). Development of
Virology 248, 295–304. a syngeneic mouse model for events related to ovarian cancer. Carcinogene-
sis 21, 585–591.
Holland, E.C., and Varmus, H.E. (1998). Basic fibroblast growth factor in-
duces cell migration and proliferation after glia-specific gene transfer in mice. Schaefer-Klein, J., Givol, I., Barsov, E.V., Whitcomb, J.M., VanBrocklin, M.,
Proc. Natl. Acad. Sci. USA 95, 1218–1223. Foster, D.N., Federspiel, M.J., and Hughes, S.H. (1998). The EV-O-derived
cell line DF-1 supports the efficient replication of avian leukosis-sarcoma
Holland, E.C., Hively, W.P., DePinho, R.A., and Varmus, H.E. (1998). A consti-
viruses and vectors. Virology 248, 305–311.
tutively active epidermal growth factor receptor cooperates with disruption
of G1 cell-cycle arrest pathways to induce glioma-like lesions in mice. Genes Shankaran, V., Ikeda, H., Bruce, A.T., White, J.M., Swanson, P.E., Old, L.J.,
Dev. 12, 3675–3685. and Schreiber, R.D. (2001). IFNgamma and lymphocytes prevent primary
tumour development and shape tumour immunogenicity. Nature 410, 1107–Holland, E.C., Celestino, J., Dai, C., Schaefer, L., Sawaya, R.E., and Fuller,
1111.G.N. (2000). Combined activation of Ras and Akt in neural progenitors in-
duces glioblastoma formation in mice. Nat. Genet. 25, 55–57. Shayesteh, L., Lu, Y., Kuo, W.L., Baldocchi, R., Godfrey, T., Collins, C.,
Pinkel, D., Powell, B., Mills, G.B., and Gray, J.W. (1999). PIK3CA is implicatedHolschneider, C.H., and Berek, J.S. (2000). Ovarian cancer: epidemiology,
as an oncogene in ovarian cancer. Nat. Genet. 21, 99–102.biology, and prognostic factors. Semin. Surg. Oncol. 19, 3–10.
Sun, M., Wang, G., Paciga, J.E., Feldman, R.I., Yuan, Z.Q., Ma, X.L., Shelley,Hughes, S.H., Greenhouse, J.J., Petropoulos, C.J., and Sutrave, P. (1987).
S.A., Jove, R., Tsichlis, P.N., Nicosia, S.V., and Cheng, J.Q. (2001). AKT1/Adaptor plasmids simplify the insertion of foreign DNA into helper-indepen-
PKBalpha kinase is frequently elevated in human cancers and its constitutivedent retroviral vectors. J. Virol. 61, 3004–3012.
activation is required for oncogenic transformation in NIH3T3 cells. Am. J.
Pathol. 159, 431–437.Jacks, T., Remington, L., Williams, B.O., Schmitt, E.M., Halachmi, S., Bron-
son, R.T., and Weinberg, R.A. (1994). Tumor spectrum analysis in p53-
Suzuki, M., Saito, S., Saga, Y., Ohwada, M., and Sato, I. (2000). Mutationmutant mice. Curr. Biol. 4, 1–7.
of K-RAS protooncogene and loss of heterozygosity on 6q27 in serous and
mucinous ovarian carcinomas. Cancer Genet. Cytogenet. 118, 132–135.Johnson, L., Mercer, K., Greenbaum, D., Bronson, R.T., Crowley, D., Tuve-
son, D.A., and Jacks, T. (2001). Somatic activation of the K-ras oncogene
Teneriello, M.G., Ebina, M., Linnoila, R.I., Henry, M., Nash, J.D., Park, R.C.,causes early onset lung cancer in mice. Nature 410, 1111–1116.
and Birrer, M.J. (1993). p53 and Ki-ras gene mutations in epithelial ovarian
neoplasms. Cancer Res. 53, 3103–3108.Kido, M., and Shibuya, M. (1998). Isolation and characterization of mouse
ovarian surface epithelial cell lines. Pathol. Res. Pract. 194, 725–730.
Wang, Z.R., Liu, W., Smith, S.T., Parrish, R.S., and Young, S.R. (1999). c-
myc and chromosome 8 centromere studies of ovarian cancer by interphaseLynch, H.T., Casey, M.J., Lynch, J., White, T.E., and Godwin, A.K. (1998).
Genetics and ovarian carcinoma. Semin. Oncol. 25, 265–280. FISH. Exp. Mol. Pathol. 66, 140–148.
Young, J.A., Bates, P., and Varmus, H.E. (1993). Isolation of a chicken geneMok, S.C., Bell, D.A., Knapp, R.C., Fishbaugh, P.M., Welch, W.R., Muto,
M.G., Berkowitz, R.S., and Tsao, S.W. (1993). Mutation of K-ras protoonco- that confers susceptibility to infection by subgroup A avian leukosis and
sarcoma viruses. J. Virol. 67, 1811–1816.gene in human ovarian epithelial tumors of borderline malignancy. Cancer
Res. 53, 1489–1492.
Yuan, Z.Q., Sun, M., Feldman, R.I., Wang, G., Ma, X., Jiang, C., Coppola,
D., Nicosia, S.V., and Cheng, J.Q. (2000). Frequent activation of AKT2 andMorita, K., Ono, Y., Fukui, H., Tomita, S., Ueda, Y., Terano, A., and Fujimori,
T. (2000). Incidence of P53 and K-ras alterations in ovarian mucinous and induction of apoptosis by inhibition of phosphoinositide-3-OH kinase/Akt
pathway in human ovarian cancer. Oncogene 19, 2324–2330.serous tumors. Pathol. Int. 50, 219–223.
62 CANCER CELL : FEBRUARY 2002
